Rutika Mehta, MD, MPH - Debbie's Dream ...

Dr. Rutika Mehta

Claim this profile

Moffitt Cancer Center

Studies Stomach Cancer
Studies Esophageal Cancer
12 reported clinical trials
29 drugs studied

Area of expertise

1Stomach Cancer
Rutika Mehta has run 5 trials for Stomach Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Esophageal Cancer
Rutika Mehta has run 4 trials for Esophageal Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Affiliated Hospitals

Image of trial facility.
Moffitt Cancer Center
Image of trial facility.
H. Lee Moffitt Cancer Center

Clinical Trials Rutika Mehta is currently running

Image of trial facility.

OBT076

for Advanced Cancer

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
Image of trial facility.

Tele-Resistance Training

for Gastrointestinal Cancer

The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.
Recruiting1 award Phase 1 & 2

More about Rutika Mehta

Clinical Trial Related6 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rutika Mehta has experience with
  • Oxaliplatin
  • Bevacizumab
  • Pembrolizumab
  • OBT076
  • Niraparib
  • SRF617

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rutika Mehta specialize in?
Is Rutika Mehta currently recruiting for clinical trials?
Are there any treatments that Rutika Mehta has studied deeply?
What is the best way to schedule an appointment with Rutika Mehta?
What is the office address of Rutika Mehta?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security